| Details |
title |
year |
| Details |
OA 04.06 SURGEON PRACTICES FOR POST RESECTION LUNG CANCER SURVEILLANCE: CO... |
2017 |
| Details |
MA 03.01 NAB-PACLITAXEL CC-486 AS SECOND-LINE TREATMENT OF ADVANCED NSCLC... |
2017 |
| Details |
MA 07.07 CLINICAL OUTCOMES AND ALK RESISTANCE MUTATIONS IN ALK+ NON-SMALL ... |
2017 |
| Details |
MA 11.03 GEFITINIB AS FIRST-LINE TREATMENT OF PLASMA CTDNA EGFR MUTATION-P... |
2017 |
| Details |
P1.01-002 TP53 MUTATIONS PREDICT FOR POOR SURVIVAL IN ALK REARRANGEMENT LU... |
2017 |
| Details |
P1.01-075 SIMULTANEOUS MULTIPLEX PROFILING OF GENE FUSIONS, METE14 MUTATIO... |
2017 |
| Details |
P1.02-034 NON-INVASIVE QUALITATIVE DIAGNOSIS OF LUNG CANCER ENABLED BY SPE... |
2017 |
| Details |
P1.03-023 THE REAL-WORLD PRACTICE OF BEVACIZUMAB PLUS CHEMOTHERAPY IN STAG... |
2017 |
| Details |
P1.06-002 THE ROLE OF COMORBIDITY IN THE MANAGEMENT AND PROGNOSIS IN NONSM... |
2017 |
| Details |
P2.01-028 CLINICAL CORRELATION BETWEEN CTCS ENUMERATION BASED ON NEW DETEC... |
2017 |
| Details |
P2.02-070 C-MET AS A BIOMARKER IN PATIENTS WITH SURGICALLY RESECTED NON-SM... |
2017 |
| Details |
P2.05-021 OCCULT NODAL METASTASIS FOLLOWING LOBECTOMY FOR CLINICAL STAGE I... |
2017 |
| Details |
P2.07-012 PATTERNS OF RESPONSE TO NIVOLUMAB IN PATIENTS WITH NON-SMALL CEL... |
2017 |
| Details |
P2.07-027 EFFICACY AND SAFETY OF NIVOLUMAB THERAPY FOR ADVANCED NSCLC IN T... |
2017 |
| Details |
P3.01-007 HETEROGENEOUS RESISTANCE MECHANISMS IN REBIOPSIES FROM EGFR-MUTA... |
2017 |
| Details |
OA 02.05 RESPECT-MESO: AN INTERNATIONAL RANDOMISED CONTROLLED TRIAL TO ASS... |
2017 |
| Details |
MA 03.01 NAB-PACLITAXEL ± CC-486 AS SECOND-LINE TREATMENT OF ADVANCED NSC... |
2017 |
| Details |
MA 07.07 CLINICAL OUTCOMES AND ALK RESISTANCE MUTATIONS IN ALK+ NON-SMALL ... |
2017 |